Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Ji Son, Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Alvarez Ballesteros, Mirella Nardo, Natalie Clark, R. Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M. Johnson, Amadeo B. Biter, Ying Yuan, Lauren P. Cobb, David M. Gershenson, Amir A. Jazaeri, Karen H. Lu, Pamela T. Soliman, Shannon N. Westin, Elizabeth D. EuscherBarrett C. Lawson, Richard K. Yang, Funda Meric-Bernstam, David S. Hong

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular profiling data at our institution between February 2010 and August 2022 were included and grouped by RAS mutation status. Overall survival was estimated by the Kaplan- Meier method, and multivariable analysis was performed using the Cox proportional hazard model. Results: Of 3,328 gynecologic cancers, 523 (15.7%) showed any RAS mutation. Patients with RAS-mutated tumors were younger (57 vs. 60 years nonmutated), had a higher prevalence of endometriosis (27.3% vs. 16.9%), and lower grades (grade 1/2, 43.2% vs. 8.1%, all P < 0.0001). The highest prevalence of KRAS mutation was in mesonephric-like endometrial (100%, n = 9/9), mesonephric-like ovarian (83.3%, n = 5/6), mucinous ovarian (60.4%), and low-grade serous ovarian (44.4%) cancers. After adjustment for age, cancer type, and grade, RAS mutation was associated with worse overall survival [hazard ratio (HR) = 1.3; P = 0.001]. Specific mutations were in KRAS (13.5%), NRAS (2.0%), and HRAS (0.51%), most commonly KRAS G12D (28.4%) and G12V (26.1%). Common co-mutations were PIK3CA (30.9%), PTEN (28.8%), ARID1A (28.0%), and TP53 (27.9%), of which 64.7% were actionable. RAS + MAPK pathway-targeted therapies were administered to 62 patients with RAS-mutated cancers. While overall survival was significantly higher with therapy [8.4 years [(95% confidence interval (CI), 5.5-12.0) vs. 5.5 years (95% CI, 4.6-6.6); HR = 0.67; P = 0.031], this effect did not persist in multivariable analysis. Conclusions: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.

Original languageEnglish (US)
Pages (from-to)2986-2995
Number of pages10
JournalClinical Cancer Research
Volume30
Issue number14
DOIs
StatePublished - Jul 15 2024

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers'. Together they form a unique fingerprint.

Cite this